https://www.medicinaeinformazione.com/ / medicinaeinformazione / einformazione CHRONIC INFLAMMATORY DISEASES ULCERATIVE COLITIS, CROHN'S DISEASE, RHEUMATOID ARTHRITIS, PSORIASIS AND PSORIATIC ARRITIS, MULTIDISCIPLINARY AND MULTIMODAL APPROACH WITH THE GOAL OF ACHIEVING REMISSION BIOLOGICAL FACTORS, CLINICAL ASPECTS, SOCIAL IMPACTS THERAPEUTIC INNOVATION TODAY IS BIOTECH AND SMALL MOLECULS ARE ABLE TO BLOCK THE INFLAMMATORY CASCADE There are apparently distant pathologies that have a common basis, inflammation. These are chronic inflammatory pathologies, such as ulcerative colitis or Crohn's disease, rheumatoid arthritis, or psoriasis and psoriatic arthritis. They have painful symptoms and in the most serious forms disabling. These are immune-mediated, multifactorial pathologies, and from numerous studies it is now clear that lifestyles, diet and other environmental factors can activate, let's say turn on inflammation, and that an important role is also played by the gut-brain axis and the composition of the microbiota. Today, knowledge of the pathogenetic mechanisms underlying chronic inflammatory diseases allows them to be managed in a global and integrated way, with a multidisciplinary and multimodal approach, with innovative drugs, small molecules that block the inflammatory cascade and cytokines. The goal is remission, for a better prognosis and quality of life. In our special today we will learn more about cellular inflammation and understand how to block it thanks to biotechnological innovation. We interviewed about this: Maria Rescigno, Head of the Laboratory of Mucosal Immunology and Microbiota at Humanitas and Deputy Vice-Rector with responsibility for Research at Humanitas University Alessandro Armuzzi, Head of the IBD Inflammatory Bowel Diseases Operating Unit at Humanitas, co-director of the IBD Center at Humanitas and lecturer at Humanitas University Antonino Spinelli, Head of the Colon and Rectal Surgery Operating Unit at Humanitas, co-director of the IBD Center at Humanitas and lecturer at Humanitas University Carlo Francesco Selmi, Head of the Rheumatology and Clinical Immunology Operating Unit at Humanitas and lecturer at Humanitas University Antonio Costanzo, Head of the Dermatology Operating Unit at Humanitas and lecturer at Humanitas University Salvo Leone, General Director of AMICI Onlus and President of EFCCA - European Federation of Crohn's & Ulcerative Colitis Associations Iole Cucinotto, Medical Director of Galápagos Italy Among the topics: What is inflammation, what causes it and what is meant by chronic inflammation. The role of the microbiota in chronic inflammatory diseases and the gut-brain axis Chronic inflammatory bowel diseases: the role of a multidisciplinary approach and how new therapies can lead to remission Surgery also plays an important role in chronic inflammatory bowel diseases, for which patients and when Another chronic inflammatory disease that has a strong impact on the lives of patients is rheumatoid arthritis, and today there are three treatment objectives Many therapeutic options available for increasingly personalized treatment for the individual patient, such as the most effective classes of drugs. Immune-mediated skin diseases, therefore psoriasis and psoriatic arthritis: the importance of the synergy between rheumatologist and dermatologist and the therapies available today. Patients' unmet needs in everyday life. Biotech innovation and translational research as drivers of new therapeutic strategies